- Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage Laboratories
- Recent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug delivery
- SPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis
- Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection
Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company that focuses on fusing traditional therapeutics with psychedelic research, recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage Laboratories, a contract research organization (“CRO”) (
https://ibn.fm/BizI3).
Recent research by the company revealed that SPU-21 liposomes have the ability to target inflamed epithelium, suggesting they can be used to target drug delivery. Further, SPU-21 can potentially be used to develop fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. According to the research, this approach may enhance therapeutic effects and decrease potential toxicity despite systemic administration of the drug.
“The production and delivery of liposomes for our upcoming study with Frontage advances SPU-21 and allows us to further study anti-arthritic activity in animals,” said Eric Weisblum, CEO of Silo Pharma. “We look forward to sharing the results of the study upon completion and data collection.”
In addition, Silo recently announced positive results in subcutaneous delivery of its novel liposomes to treat arthritic patients (
https://ibn.fm/XeEiQ). This contrasts with previous animal research testing ART-1-Cy7 liposomes using intravenous injection, suggesting that subcutaneous administration possibly trends higher than intravenous injection with fewer toxic effects. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents,” said Weisblum. “We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity.”
Silo partners with leading universities to further treatment research for various mental and physical indications. The company recently extended its exclusive option agreement with the University of Maryland, Baltimore, to explore joint-homing peptides to treat arthritis in addition to Multiple Sclerosis (“MS”). In addition, the company signed an agreement with Columbia University that granted an option to license developmental assets that include an Alzheimer’s disease formulation as well as a prophylactic treatment for post-traumatic stress disorder (“PTSD”).
Silo is dedicated to leveraging innovative solutions to help people suffering from indications such as rheumatoid arthritis, fibromyalgia, post-traumatic stress disorder (“PTSD”), Parkinson’s disease, Alzheimer’s disease, and other rare neurological disorders. The company identifies and partners with leading medical universities, providing financial resources that catalyze the progress of cutting-edge research through the clinical stage and into commercialization.
For more information, visit the company’s website at
www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at
https://ibn.fm/SILO
